| Initial model | Final model | ||||
OR | 95% CI | p-value | OR ajusted | 95% CI ajusted | p-value | |
Age ≥ 50 years | 3.85 | [0.63 - 23.56] | 0.4 |
|
|
|
Male sex | 1.70 | [1.05 - 2. 77] | 0.03 | 2.50 | [1.29 - 4.84] | 0.006 |
Socio-economical level |
|
|
|
|
|
|
High | 0.38 | [0.16 - 0.91] | 0.03 |
|
|
|
Middle | 0.71 | [0.43 - 1.18] | 0.19 | 0.50 | [0.25 - 0.98] | 0.04 |
No complication | 0.14 | [0.07 - 0.32] | 0.00 |
|
|
|
Microangiopathy | 7.33 | [3.89 -19.89] | 0.00 | 5.54 | [1.82 - 16.85] | 0.002 |
Hypertension | 7.28 | [3.77 - 14.07] | 0.00 |
|
|
|
Dyslipidemia | 1.85 | [0.99 - 3.47] | 0.054 |
|
|
|
Duration of diabetes ≥ 5years | 1.00 | [1.04 - 1.10] | 0.00 |
|
|
|
Oral Antidiabetic Drugs | 0.35 | [0.20 - 0.61] | 0.00 | 0.23 | [0.10 - 0.55] | <0.001 |
None antihypertensive drugs | 1.23 | [1.13 - 2.92] | 0.00 |
|
|
|
BRAS | 0.82 | [0.71 - 0.90] | 0.00 | 0.57 | [0.41 - 0.90] | 0.04 |
Calcium channel blockers | 0.97 | [0.19 - 0.9 ] | 0.01 |
|
|
|
Betablockers |
|
|
| 5.64 | [1.04 - 30.53] | 0.04 |